ENGN
enGene Reports Q3 2026 Financial Results
Company reveals Q3 results and BLA targeting datalimogene for urology; cash balance reported at $266 million.
ENGN news
Latest 4 stories · newest Sep 8, 2026
ENGN
enGene Appoints Heffernan Chairman Ahead of Planned 2027 FDA Approval
enGene Therapeutics named Michael Heffernan chairman, replacing Dr. Richard Glickman, to better support commercial goals. The company outlined regulatory timelines including a planned BLA submission and potential 2027 approval for its NMIBC treatment.
ENGN
ENGN
enGene reports Q2 2026 results, plans BLA filing for detalimogene in 2H 2026
enGene announced 54% complete response rate in LEGEND pivotal cohort and plans to initiate a Biologics License Application for detalimogene in the second half of 2026 pending FDA engagement. The company reduced workforce by 50% to preserve $285 million in cash and focus on regulatory and precommerci…
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same ENGN feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/ENGN/newsSTART FREE